Last Updated IST
FILE PHOTO: The Johnson and Johnson logo is seen at an office building in Singapore
Credit: Reuters Photo
Johnson & Johnson said on Thursday the US Food and Drug Administration had approved its antibody-based therapy for patients with a difficult-to-treat type of blood cancer.
The therapy, talquetamab-tgvs branded as Talvey, belongs to a class called bispecific antibodies designed to bring a cancer cell and an immune cell together so the body's immune system can kill the cancer.
Talvey was approved as a weekly or biweekly subcutaneous, or under-the-skin, injection, the company said.
Deccan Herald is on WhatsApp Channels | Join now for Breaking News & Editor's Picks